Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Keysight Technologies, Inc. KEYS and recommended buying the same. “Terrific business, niche business,” he added.

Supporting his view, JPMorgan analyst Samik Chatterjee, on Dec. 16, upgraded Keysight from Neutral to Overweight and announced a $200 price target.

Shares Views On These Health Care Names

Cramer recommended to wait for ADMA Biologics, Inc. ADMA to come down before pulling the trigger. “I don't have a catalyst,” he noted.

The company's stock has jumped more than 206% over the past year.

“I just think that they should be making money,” Cramer said when asked about NovoCure Limited NVCR. “Let's see some money made by Novocure and then we can get behind it.”

Novocure, meanwhile, on Jan. 13, reported preliminary net revenues for FY2024 of $605.2 million and preliminary net revenues of $161.3 million for the fourth quarter.

Other Stocks In Focus

When asked about Lockheed Martin Corporation LMT, he said, “I do not want to get in the way of the Palantir buzz saw because that's very close to Elon Musk.”

Lockheed Martin, meanwhile, on Jan. 28, reported mixed fourth-quarter 2024 results. The company reported a net sales decline of 1.3% year-over-year to $18.622 billion, missing the consensus of $18.91 billion. LMT reported Adjusted EPS of $7.67, beating the consensus of $6.64.

Price Action:

• Lockheed Martin shares fell 0.7% to settle at $454.36 on Wednesday.
• ADMA Biologics shares gained 1.3% to close at $16.38 during the session.
• Novocure shares fell 0.2% to settle at $25.52 on Wednesday.
• Keysight shares rose 0.2% to settle at $168.33 on Wednesday.

Read Next:

• Jim Cramer: This Industrial Stock Is ‘Absolutely Terrific’, First Solar Is ‘Very Inexpensive’

Image: Shutterstock